ASH2020: VelosBio’s ROR1 Targeted Therapy Shines in Safety Trial
On December 7th, VelosBio presented data from its Phase 1 trial at the 62nd American Society of Hematology Meeting that evaluated the safety and efficacy of their lead candidate, VLS-101, …
Read More